louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05017350: Hemostasis Using Radiofrequency Ablation for Track Bleeding
Official title: Hemostasis Using Radiofrequency Ablation for Track Bleeding After Liver Biopsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bleeding
Keywords: liver
track bleeding
radiofrequency ablation
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2021-08-23
Enrollment: 10
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding that has occurred after percutaneous biopsy of the liver.

Detailed description: Purpose: To evaluate the usefulness of hemostasis using radiofrequency ablation for track bleeding after percutaneous liver biopsy.

Method:

* Enroll patients who continue to bleed despite conservative treatment for track bleeding that has occurred after liver biopsy.
* Radiofreqeuncy ablation: Under monitoring vital signs and controlling pain with intravenous agents, the electrode is inserted into the bleeding focus. The bleeding focus is ablated.
* Hemostasis is evaluated by ultrasound (right after radiofrequency ablation), CT scan (after the radiofrequency ablation), and ultrasound (the day after radiofrequency ablation)
* If hemostasis fails using radiofrequency ablation, transarterial hepatic embolization is performed immediately.

Eligibility criteria: Inclusion Criteria:

* Ultrasound guided percutaneous liver biopsy at Samsung Medical Center
* Track bleeding after biopsy
* Persistent track bleeding even after conservative management
* Consent to this study

Exclusion Criteria:

* Not consent to this study
* \<20 years old or \>=80 years old
* Contraindication to radiofrequency ablation
* Radiofrequency ablation for track bleeding is not technically possible.
* Unstable vital signs

Primary outcomes:
measure: hemostasis rate
timeFrame: immediately after radiofrequency ablation
Secondary outcomes:
measure: complication rate
timeFrame: immediately after radiofrequency ablation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Kyoung Doo Song, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06721650: Perturbation-Based Balance Training on Trunk Proprioception and Balance in Cerebral Palsy:
Official title: Effect of Perturbation-Based Balance Training on Trunk Proprioception and Balance in Hemiplegic Cerebral Palsy: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cerebral Palsy
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 38
Sex: ALL
Minimum age (years): 8
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the effect of Perturbation-Based Balance Training on trunk proprioception and balance in hemiparetic cerebral palsy

Detailed description: Thirty-eight patients with hemiplegic cerebral palsy will participate in this study.

The patients will randomly be divided into two equal groups; the control group which received the selected physical therapy exercise program and the study group received the same exercise training program in addition to Perturbation-Based Balance Training, three times per week for three months. The evaluation methods are BIODEX, The Pediatric Balance Scale, baseline digital inclinometer.

Eligibility criteria: Inclusion Criteria:

* - Thirty-eight children hemiplegic cerebral palsy
* Age will range as (8:10) years old
* Spastic hemiplegic cerebral palsy
* Normal body mass index ranged from 1SD to -2SDaccording to BMI-for age Z score charts include an age and sex- specific BMI for children (WHO, 2007).
* Gross motor function classification system: level I\&II

Exclusion Criteria:

* • Difficulty to communicate or to understand program instructions

  * any other neurological deficits or orthopaedic abnormalities,
  * secondary musculoskeletal complication
  * vestibular problems
  * any mental impairment

Primary outcomes:
measure: BIODEX balance system
timeFrame: three months
measure: Pediatric Balance Scale
timeFrame: three months
measure: baseline digital inclinometer.
timeFrame: four weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: October 6 University
state: El-Sheikh Zayed City Giza 1133 Egypt
Study officials:
References:
Clinical trial NCT05281250: Evaluation of Physical Exercise to Prevent Functional Deterioration During Hospitalization (EFFAPRO)
Official title: Evaluation of Physical Exercise as a Protective Factor for the Loss of Functional Capacity in Patients With Metastatic Tumors During Hospitalization. Pilot Study (EFFAPRO)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cancer Patients
Hospitalized
Keywords: rehabilitation
physical activity
Physical condition
Lead sponsor: Puerta de Hierro University Hospital
Sponsor class: OTHER
First posted: 2022-03-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized study that will measure the possible benefit of supervised training during the hospitalization of patients with stage IV neoplasms in active treatment.

Detailed description: The trial is not going to be runned

Eligibility criteria: Inclusion Criteria:

* Patients with stage IV neoplasms.
* Active treatment: chemotherapy, hormone therapy, immunotherapy or targeted therapies.
* Hospitalization at Medical Oncology Departmentof the Hospital Puerta de Hierro.
* Reason for hospitalization is expected to be solved in less than two weeks.

Exclusion Criteria:

* Patients who do not wish to participate.
* Cognitive impairment.
* Hospitalization due to progression of oncological disease.
* Acute coronary syndrome or bone fracture in limbs during the previous three months.

Primary outcomes:
measure: Functional capacity
timeFrame: Through study completion (average 10 days)
Secondary outcomes:
measure: Strength
timeFrame: Through study completion (average 10 days).
measure: Cardiorespiratory condition
timeFrame: Through study completion (average 10 days)
measure: Daily physical activity
timeFrame: Through study completion (average 10 days)
measure: Fatigue-FACIT
timeFrame: Through study completion (average 10 days)
measure: Fatigue-PERFORM
timeFrame: Through study completion (average 10 days)
measure: Life quality: Q30 questionnaire
timeFrame: Through study completion (average 10 days)
measure: Anxiety and depression
timeFrame: Through study completion (average 10 days)
measure: Length of hospital stay
timeFrame: Through study completion (average 10 days).
Other outcomes:
Locations:
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro
state: Madrid
Study officials:
affiliation: Puerta de Hierro University Hospital
name: Ana Ruiz Casado
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01489150: Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure
Official title: Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercapnic Respiratory Failure
Keywords: Acute respiratory failure
Hypercapnia
Non invasive ventilation
End-tidal CO2
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2011-12-09
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Intensive care unit patients equipped with arterial line requiring non invasive ventilation because of acute hypercapnic respiratory failure

Brief summary: In patients treated by Non invasive ventilation (NIV) due to acute hypercapnic respiratory failure, the interest of using the End-tidal Co2 measurement device "Capnostream" to evaluate PaCo2 and PaCo2 variations over time will be evaluated. Measurements will be done under normal expiration and under prolonged active and passive expiration maneuvers.


Eligibility criteria: Inclusion Criteria:

* ICU patient equipped with arterial line
* NIV requirement
* Hypercapnia: PaCO2 \> 45mmhg

Exclusion Criteria:

* Severe hemodynamic instability
* Severe psychiatric disorders
* nasal lesions
* denied consent

Primary outcomes:
measure: Comparison between EtCO2,PaCO2 and PaCO2 variation under NIV during both spontaneous expiration and prolonged expiration
timeFrame: Sixty minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Intensive care and burn unit, University Hospital of Lausanne
Study officials:
affiliation: University of Lausanne Hospitals
name: Philippe Jolliet, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Piquilloud L, Thevoz D, Jolliet P, Revelly JP. End-tidal carbon dioxide monitoring using a naso-buccal sensor is not appropriate to monitor capnia during non-invasive ventilation. Ann Intensive Care. 2015 Feb 12;5:2. doi: 10.1186/s13613-014-0042-8. eCollection 2015.
Clinical trial NCT00852150: Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible?
Official title: Reproducibility of Modified Lanza Scale for the Reporting of Gastritis and Duodenitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastritis
Duodenitis
Keywords: gastritis
duodenitis
inter-rater reliability
intra-rater reliablity
gastroscopy
duodenoscopy
Lead sponsor: Ruttonjee Hospital
Sponsor class: OTHER
First posted: 2009-02-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all patient undergoing upper endoscopy after informed consent is obtained

Brief summary: The modified Lanza scale (Lanza FL, 1984) has been widely utilized to grade the degree of gastritis and duodenitis. However, the inter-rater or intra-rater reproducibility of this scale has never been validated. As a quality improvement program, it is important to study the reproducibility of the scale between different operators and the operators himself.

Method: During upper endoscopic examinations, one investigator performed the procedure and the second investigator look at the endoscopic image. The degree of gastritis and duodenitis is graded. The results of the grading are blinded to the other investigator.

The endoscopic video is stored for reassessment to determine the intra-rater reliability. The patient identifier is stored in serial number. The investigator will not retrieve the report of the first assessment during the second assessment.


Eligibility criteria: All patients undergo upper endoscopy are included after written informed consent is obtained

Primary outcomes:
measure: Kappa coefficient for the intra and inter-rater agreement
Secondary outcomes:
Other outcomes:
Locations:
city: Wan Chai
country: China
facility: Ruttonjee Hospital
state: Hong Kong
city: Hong Kong
country: China
facility: Ruttonjee Hospital
Study officials:
affiliation: Department of Medicine, Ruttonjee Hospital
name: Fook Hong Ng, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05952050: Different Administration Routes of Dexmedetomidine on Postoperative Delirium
Official title: Effect of Different Administration Routes of Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing General Anesthesia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Dexmedetomidine
Postoperative Delirium
General Anesthesia
Lead sponsor: Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Zhongshan Hospital Of Traditional Chinese Medicine
First posted: 2023-07-19
Enrollment: 120
Sex: ALL
Minimum age (years): 65
Maximum age (years): 99
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (POD) in elderly patients. Nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. The current study aimed to compare the effect of different administration routes of dexmedetomidine on POD in elderly patients.


Eligibility criteria: Inclusion Criteria:

Older than 65 years; General anesthesia for more than two hours;

Exclusion Criteria:

-

Primary outcomes:
measure: The frequency of delirium during the first 3 postoperative days
timeFrame: 3 days
Secondary outcomes:
measure: The incidence of postoperative sore throat
timeFrame: 3 days
measure: The incidence of sleep quality
timeFrame: 3 days
Other outcomes:
Locations:
city: Zhongshan
country: China
facility: Weitao Chen
state: Guangdong
Study officials:
References:
Clinical trial NCT00157950: Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
Official title: An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Papillomavirus Infections
Keywords: Human Papilloma Virus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 176
Sex: FEMALE
Minimum age (years): 9
Maximum age (years): 23
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.


Eligibility criteria: Inclusion Criteria:

* Girls ages 9 to 15 years (must not yet have had coitarche)
* Healthy females ages 16 to 23 years (individuals with a lifetime history of 0 to 3 male or female sexual partners)

Exclusion Criteria:

All Subjects:

* History of known prior vaccination with an HPV vaccine.

Women Ages 16 to 23 Only:

* Individuals with any prior history of genital warts or treatment for genital warts.
* Individuals with \> 3 lifetime male or female sexual partners.

Primary outcomes:
measure: Number of Participants Who Seroconvert to HPV 6.
timeFrame: Week 4 Postdose 3
measure: Number of Participants Who Seroconvert to HPV 11.
timeFrame: Week 4 Postdose 3
measure: Number of Participants Who Seroconvert to HPV 16.
timeFrame: Week 4 Postdose 3
measure: Number of Participants Who Seroconvert to HPV 18.
timeFrame: Week 4 Postdose 3
Secondary outcomes:
measure: Number of Participants With Adverse Experiences
timeFrame: Overall study including 14 calendar days after the last vaccination visit.
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, Park SY. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1013-9. doi: 10.1111/j.1525-1438.2007.01123.x. Epub 2007 Nov 6.
citation: Hurt L, Nsouli-Maktabi H, Rohrbeck P, Clark LL. Use of quadrivalent human papillomavirus vaccine and the prevalence of antibodies to vaccine-targeted strains among female service members before and after vaccination. MSMR. 2016 Feb;23(2):6-13.
Clinical trial NCT02174250: The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Official title: Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Parkinson's Disease
Keywords: PD
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Kyowa Hakko Kirin Pharma, Inc.
First posted: 2014-06-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to test whether Rifampin affects blood levels of istradefylline in humans. Rifampin could possibly decrease istradefylline levels.


Eligibility criteria: Inclusion Criteria:

* Healthy non-smoking male and post-menopausal female subjects
* Body Mass Index: 18.0-35.0 kg/m2, inclusive
* Subjects must not be taking drugs that are moderate to potent inhibitors of CYP3A4 or CYP1A2.
* Subjects without clinically significant medical history in the judgment of the investigator
* Subjects without clinically significant laboratory or ECG abnormalities

Exclusion Criteria:

* Females that are pregnant or lactating
* Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study;
* Known history of treatment for drug or alcohol addiction within the previous 12 months;
* Subjects with an average alcohol intake of more than 2 units per day or 14 units per week up to 48 hours prior to the istradefylline dose on Day 1. One unit of alcohol is ½ pint of beer (285 mL) or 1 glass of spirits (25 mL) or 1 glass of wine (125 mL);
* Donated or lost \> 500 mL of blood within 3 months prior to istradefylline dose on Day 1 of Period 1;
* Positive test results for human immunodeficiency virus (HIV) or Hepatitis B surface antigen, or Hepatitis C;
* Positive test results for drugs of abuse at screening;
* Unable, or unwilling to tolerate multiple venipunctures;
* Difficulty fasting or eating the standard meals that will be provided;
* Use of tobacco or nicotine-containing products within 90 days of the study start to the Follow-up visit

Primary outcomes:
measure: Area under the concentration-time curve from time zero to infinity (AUC0 ∞) and Observed maximum plasma concentration (Cmax) of istradefylline
timeFrame: Intermittently for a total of 62 days
Secondary outcomes:
measure: Number of serious adverse events, and non-serious adverse events
timeFrame: Continuously for up to 74 days
Other outcomes:
Locations:
city: Tempe
country: United States
facility: Celerion, Inc.
state: Arizona
Study officials:
affiliation: Kyowa Hakko Kirin Pharma, Inc.
name: Marc Cantillon, M.D.
role: STUDY_CHAIR
affiliation: Kyowa Hakko Kirin Pharma, Inc.
name: Amy Zhang, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00055250: A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer
Official title: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pancreatic Cancer
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2003-02-24
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
* Tumor that can be measured by x-ray or scan
* Adequate organ function

Exclusion Criteria:

* Inability to swallow capsules
* Documented brain metastases
* Prior chemotherapy or biological therapy for this disease

Primary outcomes:
measure: 6-month survival
Secondary outcomes:
measure: Toxicity
measure: tumor response
measure: PK
Other outcomes:
Locations:
city: Lakeland
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
state: Florida
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT06000150: Characteristics of Trachomatous Corneal Opacity in Fayoum University Hospital
Official title: Characteristics of Trachomatous Corneal Opacity in Fayoum University Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corneal Opacity
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with trachomatous corneal opacity

Brief summary: The purpose of this study is to assess the characteristics of trachomatous corneal opacity in patients with signs of trachoma using Anterior segment Optic coherence tomography and Pentacam

Detailed description: After approval of the local institutional ethics committee and local institutional review board, patient presented to Fayoum University Hospital was examined for corneal opacity with signs of trachoma after a detailed informed consent was signed by eligible patients and investigated by Anterior Segment Optic coherence Tomography and Pentacam.

Descriptive statistics were presented in the form of mean and standard deviation for numerical variables while numbers and percentages are used for the categorical variables.

Paired samples t-test was used to study anterior segment Optic Coherence tomography and pentacam in evaluating corneal thickness. Bland-Altman plot was used to study the agreement between the two methods IBM SPSS version 28 for Windows software was used for the analysis and Stata 16 was used for the Bland-Altman plot. A p-value of \< 0.05 was considered significant.

Eligibility criteria: Inclusion Criteria:

* patients with corneal opacity accompanied by signs of trachoma

Exclusion Criteria:

* corneal opacity due other causes
* history of corneal surgery

Primary outcomes:
measure: Corneal imaging
timeFrame: we will recruit patients who meer the inclusion criteria during the study period february-August 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: Fayoum University
Study officials:
References: